Property | Value |
Name | Age related metabolic syndrome among Fars ethnic women in Gorgan, Iran. |
Description | Original article:- Biochemistry and Biophysics Abdoljalal Marjani1* & Najmeh Shahini2 1Department of Biochemistry and Biophysics, Metabolic Disorders Research Center, Gorgan Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Golestan province, Iran. 2Medical Student, Student Reaserch Commitee, Golestan University of Medical Sciences, Gorgan, Iran.
Abstract:- Background: Studies have been shown that the prevalence of metabolic syndrome changes among different ethnic and sex groups. Objective: We determined age related prevalence of metabolic syndrome among Fars ethnic women. Study design: Health center based study. Setting: Metabolic Disorders Research Center in Gorgan. Participants: 160 Fars adult women. Sampling: randomized sampling method. Results: The most age distribution was in ages from 35 to 40 years (50%). There were significant differences between the mean value of waist circumferences, fasting blood glucose, body mass index and triglyceride among subjects with and without metabolic syndrome in age groups 20-24 and 25-29 years old (P<0.05). HDL-cholesterol and LDL-cholesterol levels were significantly decreased and increased in these age groups, respectively (P<0.05). There were also significant increases in fasting blood glucose and triglyceride levels among subjects with and without metabolic syndrome in age groups 30-34 and 35-40 years old (P<0.05). There were decreased HDL-cholesterol in age group 30-34 years old (P<0.05). There were significant differences in the prevalence of metabolic syndrome in age groups 20-24 and 30-34 years old (P<0.05). Conclusion: High waist circumference, Fasting Glucose and triglyceride, and low HDL cholesterol are more effective among subjects with metabolic syndrome and, in the presence of obesity may elevate the risk of coronary heart disease. The increasing number of overweight and obese subjects in our study makes certain that metabolic syndrome begins from young age and will continue as age progresses. It seems that women require altering their life style to prevent cardiovascular complications.
Keywords:- Gorgan, metabolic syndrome, age related, ethnic group.
References:- 1.Miranda PJ, DeFronzo RA, Califf RM and Guyton JR. Metabolic syndrome: definition, pathophysiology, and mechanisms. Am Heart J. 2005; 149: 33-45. 2.Kylin E. Studien ueber das Hypertonie-Hyperglykamie - Hyperurikamiesyndrom. Zentrallblatt fuer Innere Medizin 1923; 44: 105-27. 3.Reaven G. Mand Banting Lecture. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607. 4.Meigs JB, Wilson PW, Nathan DM, et al. Prevalence and characteristics of the metabolic syndrome in the San Antonio heart and Framingham offspring studies, Diabetes 2003 52: 2160-7. 5.Burke JP, Williams K, Gaskill SP, et al. Rapid rise in the incidence of type 2 diabetes from 1987 to 1996: Results from the San Antonio heart study, Arch Intern Med. 1999; 41: 1450-6. 6.King H, Zimmet P. Trends in the prevalence and incidence of diabetes: Noninsulin dependent diabetes mellitus, World Health Stat 1998; 41: 190-6. 7.Cameron AJ, Shaw JE and Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations, Endocrinol Metab Clin N Am. 2004; 33: 351-75. 8.Gupta A, Gupta R, Sarna M, Rastogi S, Grupta VP and Kothari K. Prevalence of diabetes, impaired fasting glucose and insulin resistance syndrome in an urbanIndian population, Diabetes Res Clin Pract. 2003; 61: 69-76. 9.Ford ES, Giles WH and Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey, JAMA. 2002; 287: 356-9. 10.Balkau B, Vernay M, Mhamdi L, Novak M, Arondel D and Vol S, et al. The D.E.S.I.R Study Group. The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome, The French D.E.S.I.R. study. Diabetes Metab. 2003; 29: 526-32. 11.Ramachandran A, Snehalatha C, Satyavani K, Sivasankariand S, Vijay V. Metabolic syndrome in urban Asian Indian Adults-a population study using modified ATP III criteria., Diabetes Res Clin Pract. 2003; 60: 199-204. 12.Lloyd-Jones D , Adams R, Carnethon M, De SG, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, Circulation 2009; 119: 480-6. 13.Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimerand Mac AR, Farlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia, West of Scotland Coronary Prevention Study Group, N Engl J Med. 1995; 333: 1301-7. 14.Downs JR, Clearfield M, Weis S, Whitney E, Shapiroand DR, Beerc PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/ TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study, JAMA. 1998; 279:1615-22. 15.Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR and Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S, Circulation 2001; 104: 3046-51. 16.Qiao Q. Comparison of different definitions of the metabolic syndrome in relation to cardiovascular mortality in European men and women, Diabetologia 2006; 49: 2837-46. 17.Hildrum B, Mykletun A, Hole T , Midthjell K, DahlAA. Age-specific prevalence of the metabolic syndrome defined by the International Diabetes Federation and the National Cholesterol Education Program: the Norwegian HUNT 2 study, BMC Public Health 2007; 7: 220. 18.Meigs JB. “Invited commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors,” American Journal of Epidemiology 2000; 10: 908–12. 19.Duncan GE, Li SM, Zhou XH. Prevalence and trends of a metabolic syndrome phenotype among U.S. Adolescents, 1999-2000. Diabetes Care 2004; 27: 2438-43. 20.Esmaillzadeh A, Mirmiran P, Azadbakht L, Etemadi A, Azizi F. High prevalence of the metabolic syndrome in Iranian adolescents. Obesity (Silver Spring) 2006; 14:377-82. 21.Rodriguez-Moran M, Salazar-Vazquez B, Violante R, Guerrero-Romero F: Metabolic syndrome among children and adolescents aged 10-18 years. Diabetes Care 2004; 27:2516-2517. 22.Saito I, Mori M, Shibata H, Hirose H, Tsujioka M, Kawabe H. Prevalence of metabolic syndrome in young men in Japan. J Atheroscler Thromb. 2007; 14:27-30. 23.Johnson WD, Kroon JJ, Greenway FL, Bouchard C, Ryan D, Katzmarzyk PT. Prevalence of risk factors for metabolic syndrome in adolescents: National Health and Nutrition Examination Survey (NHANES), 2001-2006. Arch Pediatr Adolesc Med. 2009; 163:371-7. 24.Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Adult Treatment Panel III). JAMA 2001; 285: 2486-97. 25.World Health Organization. Prevention and Management of the Global Epidemic of Obesity. Report of the WHO Consultation on Obesity. WHO: Geneva, 1998 (Technical Report Series, No. 894). 26.Dalton M, Cameron AJ, Zimmet PZ, Shaw JE, Jolley D, Dunstan DW, Welborn TA. AusDiab Steering Committee. Waist circumference, waist-hip ratio and body mass index and their correlation with cardiovascular disease risk factors in Australian adults. J Intern Med. 2003; 254: 555-63. 27.Sarrafzadegan N, Kelishadi R, Baghaei A, Hussein SG, Malekafzali H, Mohammadifard N, et al. Metabolic syndrome: an emerging public health problem in Iranian women: Isfahan Healthy Heart Program. Int J Cardiol. 2008; 131(1): 90-6. 28.Kozan O, Oguz A, Abaci A, Erol C, Ongen Z, Temizhan A, et al. Prevalence of the metabolic syndrome among Turkish adults. Eur J Clin Nutr. 2007; 61(4): 548-53. 29.Hadaegh F, Zabetian A, Tohidi M, Ghasemi A, Sheikholeslami F, Azizi F. Prevalence of metabolic syndrome by the Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions and their association with coronary heart disease in an elderly Iranian population. Ann Acad Med Singapore 2009; 38(2): 142-9. 30.Mukuddem-Petersen J, Snijder MB, van Dam RM, Dekker JM, Bouter LM, Stehouwer CD, et al. Sagittal abdominal diameter: no advantage compared with other anthropometric measures as a correlate of components of the metabolic syndrome in elderly from the Hoorn Study. Am J Clin Nutr 2006; 84(5): 995-1002. 31.Sanisoglu SY, Oktenli C, Hasimi A, et al. Prevalence of metabolic syndrome-related disorders in a large adult population in Turkey. BMC Public Health 2006; 6:92. 32.Ford ES, Li C, Imperatore G, Cook S. Age, sex, and ethnic variations in serum insulin concentrations among US youth: findings from the National Health and Nutrition Examination Survey 1999–2002. Diabetes Care 2006; 29:2605–11. 33.Park YW, Zhu S, Palaniappan L, et al. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. Arch Intern Med. 2003; 163:427–36. 34.Grundy SM. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation 1997; 95:1– 4. 35.Reddy KS, Shah P, Shrivastava U, Prabhakaran D, Joshi M, Puri SK, et al. Coronary heart disease risk factors in an industrial population of north India. Can J Cardiol. 1997; 13(Suppl. B):26B. 36.Krishnaswami S. Conventional risk factors for coronary artery disease in Indian patients. In: Sethi KK, editor. Coronary Artery Disease in Indians: a Global Perspective. Bombay: Cardiological Society of India, 1998; 73– 82. 37.Orio F Jr, Palomba S, Cascella T, Savastano S, Lombardi G, Colao A. Cardiovascular complications of obesity in adolescents. J Endocrinol Invest. 2007;30: 70–80. 38.Ford ES, Mokdad AH, Giles WH. Trends in waist circumference among US adults. Obes Res. 2003; 11: 1223–31. 39.Hillege HL, Fidler V, Diercks GF, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106:1777–82. 40.Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683–9. 41.Meigs JB, D’Agostino RB Sr, Wilson PW, Cupples LA, Nathan DM, Singer DE. Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study. Diabetes 1997; 46:1594–1600. 42.Natali A, Toschi E, Baldeweg S, et al. Clustering of insulin resistance with vascular dysfunction and lowgrade inflammation in type 2 diabetes. Diabetes 2006; 55:1133–40. 43.Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics—2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115(4):e69–e171. 44.Gill H, Mugo M, Whaley-Connell A, Stump C, Sowers JR. The key role of insulin resistance in the cardiometabolic syndrome. Am J Med Sci. 2005; 330: 290–294. 45.Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab. 2004; 89: 2595–2600. 46.Foy CG, Foley KL, D’Agostino RB Jr, Goff DC Jr, Mayer-Davis E, Wagenknecht LE. Physical activity, insulin sensitivity, and hypertension among US adults: findings from the Insulin Resistance Atherosclerosis Study. Am J Epidemiol. 2006; 163:921–928. 47.Straznicky NE, Lambert EA, Lambert GW, Masuo K, Esler MD, Nestel PJ. Effects of dietary weight loss on sympathetic activity and cardiac risk factors associated with the metabolic syndrome. J Clin Endocrinol Metab. 2005; 90:5998–6005. 48.Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003–2006. Natl Health Stat Report 2009; 5:1–7. 49.Kwasniewska M, Kaleta D, Dziankowska-Zaborszczyk E, Drygas W. Healthy behaviors, lifestyle patterns and sociodemographic determinants of the metabolic syndrome. Cent Eur J Public Health 2009; 17:14–19. 50.Yang FY, Wahlqvist ML, Lee MS. Body mass index (BMI) as a major factor in the incidence of the metabolic syndrome and its constituents in unaffected Taiwanese from 1998 to 2002. Asia Pac J Clin Nutr. 2008; 17:339–51. 51.Reeder BA, Senthilselvan A, Despres JP, et al. The association of cardiovascular disease risk factors with abdominal obesity in Canada. Canadian Heart Health Surveys Research Group. CMAJ. 1997; 157 (suppl 1):S39-S45. 52.Wang Y, Rimm EB, Stampfer MJ, Willett WC, Hu FB. Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. Am J Clin Nutr. 2005; 81: 555-63. 53.Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. Geneva, World Health Organization, 1995 (WHO Technical Report Series, No. 854. 54.Foucan L, Hanley J, Deloumeaux J, Suissa S. Body mass index (BMI) and waist circumference (WC) as screening tools for cardiovascular risk factors in Guadeloupean women. J Clin Epidemiol. 2002; 55: 990-6. 55.Zabetian A, Hadaegh F, Azizi F. Prevalence of metabolic syndrome in Iranian adult population, concordance between the IDF with the ATPIII and the WHO definitions. Diabetes Rese Clin Pract. 2007; 77: 251-7. 56.Schmidt MI, Watson RL, Duncan BB, et al. Clustering of dyslipidemia, hyperuricemia, diabetes, and hypertension and its association with fasting insulin and central and overall obesity in a general population. Atherosclerosis Risk in Communities Study Investigators.bMetabolism 1996; 45: 699-706. 57. Bahrami H. Sadatsafavi M, Pourshams A, et al. Obesity and hypertension in an Iranian cohort study; Iranian women experience higher rates of obesity and hypertension than American women. BMC Public Health 2006; 20: 158. 58.National Institutes of Health, National Heart, Lung, and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Obes Res. 1998; 6 (suppl 2): S51-S210. 59.Phillips NR, Havel RJ, Kane JP. Levels and interrelationships of serum and lipoprotein cholesterol and triglycerides: association with adiposity and the consumption of ethanol, tobacco, and beverages containing caffeine. Arteriosclerosis 1981; 1: 13-24. 60.Schaefer EJ, Lamon-Fava S, Ordovas JM, et al. Factors associated with low and elevated plasma high density lipoprotein cholesterol and polipoprotein A-I levels in the Framingham Offspring Study. J Lipid Res. 1994; 35: 871-82. 61.Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998; 81: 7B-12B. 62.Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837- 47. 63.Vega GL, Grundy SM. Hypoalphalipoproteinemia (low high density lipoprotein) as a risk factor for coronary heart disease. Curr Opin Lipidol. 1996; 7: 209-16.
*Correspondence address: Abdoljalal Marjani., (Associated Prof. in Biochemistry), Gorgan Faculty of Medicine, Department of Biochemistry and Biophysics, Metabolic Disorders Research Center, Gorgan Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Golestan province, .Iran. Tel & Fax: +98(171)4421651 & 4440225.
|
Filename | Marjani Abdoljalal et al.(929-935).pdf |
Filesize | 244.85 kB |
Filetype | pdf (Mime Type: application/pdf) |
Creator | admin |
Created On: | 05/06/2013 00:00 |
Viewers | Everybody |
Maintained by | Editor |
Hits | 2963 Hits |
Last updated on | 06/02/2013 04:47 |
Homepage | |
CRC Checksum | |
MD5 Checksum |